Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Grace Therapeutics, Inc
GRCE
Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel...
, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GRCE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 1:45pm
Acasti Pharma (NASDAQ:ACST): A Promising Specialty Pharmaceu
https://beyondspx.com/2024/07/31/acasti-pharma-nasdaqacst-a-promising-specialty-pharmaceutical-company-focused-on-rare-and-orphan-diseases-2/
(80)
•••
bingostar
X
Post by
bingostar
on Dec 22, 2022 6:08pm
the perfect situation
With a market cap trading under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you cannot dream of a better scenario . On top of it the CEO Pierre
...more
(56)
•••
Canadian_101
X
Comment by
Canadian_101
on Nov 21, 2022 3:26pm
RE:GTX-104 positive results
No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when they delayed their results for capri, I would not invest a dime in
...more
(80)
•••
bingostar
X
Post by
bingostar
on May 18, 2022 1:19pm
GTX-104 positive results
As annouced today: Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints :: Acasti Pharma Inc. (ACST) They have 3 products
...more
(3017)
•••
Betteryear2
X
Post by
Betteryear2
on Apr 25, 2022 8:45am
Acasti Pharma to Present
LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial
...more
(15)
•••
alanmar1
X
Post by
alanmar1
on Apr 03, 2022 4:21pm
acasti
Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never been fully ex[plained.Later the promise of licensing Care pre
...more
(60)
•••
flush777
X
Comment by
flush777
on Jan 05, 2022 1:56pm
RE:Over 200K on the bid, which is 1% of outstanding shares
Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low hanging fruit awaiting conference news... hopefully very very
...more
(60)
•••
flush777
X
Comment by
flush777
on Jan 05, 2022 1:51pm
RE:Oppenheimer report on Acasti, outperform, target US $6
ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report ... except that it takes time for analysis and thoughts and yes, I
...more
(60)
•••
flush777
X
Post by
flush777
on Jan 05, 2022 12:45pm
Oppenheimer report on Acasti, outperform, target US $6
Report dated Dec 21, 2021 ... Hum, graph looks great for any potential investor ...
(60)
•••
flush777
X
Post by
flush777
on Jan 05, 2022 12:26pm
Over 200K on the bid, which is 1% of outstanding shares
being whittled away at $1.85. Really good sign for the future!
(52)
•••
Francine01
X
Post by
Francine01
on Dec 06, 2021 11:12am
SP Value
SP value is below cash in bank account. I didn't knew that this could be possible for a plublic company. Good job Jan!
(56)
•••
Canadian_101
X
Comment by
Canadian_101
on Nov 06, 2021 10:12am
RE:For the record
What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me something was majorly wrong when they delayed the
...more
(4)
•••
19LDS84
X
Comment by
19LDS84
on Oct 06, 2021 8:45pm
RE:Awarded Composition-of-Matter Patents for GTX-101
The best news here is the parents are good until 2036, which gives Jan plenty of time to f#$k this up again.... glta
(3017)
•••
Betteryear2
X
Post by
Betteryear2
on Oct 06, 2021 8:34am
Awarded Composition-of-Matter Patents for GTX-101
LAVAL, Qubec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office
...more
(15)
•••
alanmar1
X
Post by
alanmar1
on Oct 02, 2021 11:01am
Acasti pharma
This is directed to Francine ,a dedicated ACST follower and righty so based on data available. Francine, if you still own ACST stock I recomend you move some of your investment into WML. You
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities